|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 121 | 2019 | Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression | DE BROUWER, Edward; PEETERS, Liesbet; BECKER, Thijs; Altintas, A.; Soysal, A.; VAN WIJMEERSCH, Bart; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Luliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y. | Journal Contribution | M |
| 122 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 123 | 2019 | Therapeutic lag in relapsing multiple sclerosis | ROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T. | Journal Contribution | M |
| 124 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 125 | 2019 | Effectiveness and safety of Tetrahydrocannabinol - Cannabidiol Oromucosal spray in Belgian patients with multiple sclerosis spasticity: a retrospective data collection | POPESCU, Veronica; Vos, C.; van Dael, V.; Raeymaekers, G.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 126 | 2019 | A pilot study of the effects of running training on visuospatial memory in MS: A stronger functional embedding of the hippocampus in the default-mode network? | Huiskamp, Marijn; MOUMDJIAN, Lousin; VAN ASCH, Paul; POPESCU, Veronica; Schoonheim, Menno Michiel; Steenwijk, Martijn D.; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Geurts, Jeroen J. G.; FEYS, Peter; Hulst, Hanneke E. | Journal Contribution | A1 |
| 127 | 2019 | Effects of an individual 12-week communitylocated “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis | FEYS, Peter; MOUMDJIAN, Lousin; VAN HALEWYCK, Florian; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; VAN ASCH, Paul | Journal Contribution | A1 |
| 128 | 2019 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis | Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Onofrj, Marco; Lugaresi, Alessandra; Ozakbas, Serkan; Kappos, Ludwig; Kuhle, Jens; Terzi, Murat; Lechner-Scott, Jeannette; Boz, Cavit; Grand'Maison, Francois; Prevost, Julie; Sola, Patrizia; Ferraro, Diana; Granella, Franco; Trojano, Maria; Bergamaschi, Roberto; Pucci, Eugenio; Turkoglu, Recai; McCombe, Pamela A.; Van Pesch, Vincent; VAN WIJMEERSCH, Bart; Solaro, Claudio; Ramo-Tello, Cristina; Slee, Mark; Alroughani, Raed; Yamout, Bassem; Shaygannejad, Vahid; Spitaleri, Daniele; Luis Sanchez-Menoyo, Jose; Ampapa, Radek; Hodgkinson, Suzanne; Karabudak, Rana; Butler, Ernest; Vucic, Steve; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut | Journal Contribution | A1 |
| 129 | 2018 | Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) | Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A. | Journal Contribution | M |
| 130 | 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 131 | 2018 | Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done! | PEETERS, Liesbet; van Munster, Caspar E.; VAN WIJMEERSCH, Bart; BRUYNDONCKX, Robin; LAMERS, Ilse; HELLINGS, Niels; POPESCU, Veronica; Thalheim, Christoph; FEYS, Peter | Journal Contribution | A1 |
| 132 | 2018 | Durable clinical efficacy of alemtuzumab in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study) | McCombe, Pamela; Boyko, Alexey N.; DeSeze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Vermersch, Patrick; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 133 | 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 134 | 2018 | Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study | D'hooghe, Marie; Van Gassen, Geert; Kos, Daphne; Bouquiaux, Olivier; Cambron, Melissa; Decoo, Danny; Lysandropoulos, Andreas; VAN WIJMEERSCH, Bart; Willekens, Barbara; Penner, Iris-Katharina; Nagels, Guy | Journal Contribution | A1 |
| 15 | 2018 | Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) | Vermersch, Patrick; Coles, Alasdair J.; Boyko, Alexey N.; De Seze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; McCombe, Pamela; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 16 | 2018 | Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) | VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K.; Wiendl, H. | Journal Contribution | M |
| 17 | 2018 | Treatment Experiences of Patients with MS: Results From the Global vs MS (TM) Survey | Bass, Ann; VAN WIJMEERSCH, Bart; Boster, Aaron; Mayer, Lori; Mandel, Matt; Sharrock, Kersten; Mitchell, Colin P.; Singer, Barry | Journal Contribution | M |
| 18 | 2018 | A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis | Laureys, Guy; Willekens, Barbara; Vanopdenbosch, Ludo; Deryck, Olivier; Selleslag, Dominik; D'Haeseleer, Miguel; De Becker, Ann; Dubois, Benedicte; Dierickx, Daan; Perrotta, Gaetano; De Wilde, Virginie; van Pesch, Vincent; Straetmans, Nicole; Dive, Dominique; Beguin, Yves; VAN WIJMEERSCH, Bart; Theunissen, Koen; Kerre, Tessa; Van de Velde, Ann | Journal Contribution | A1 |
| 19 | 2018 | Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) | VAN WIJMEERSCH, Bart; Boyko, Alexey N.; Broadley, Simon; Brassat, David; Dive, Dominique; Hupperts, Raymond M. M.; Lycke, Jan; Montalban, Xavier; Sharrack, Basil; Wray, Sibyl; Margolin, David H.; Chung, Luke; Daizadeh, Nadia; Chirieac, Madalina; Wiendl, Heinz | Journal Contribution | M |
| 20 | 2018 | Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) | Steingo, Brian; Oreja-Guevara, Celia; Alroughani, Raed; Brassat, David; Boyko, Alexey N.; McCombe, Pamela; VAN WIJMEERSCH, Bart; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; Vermersch, Patrick | Journal Contribution | M |